Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that it has acquired NOTOCORD® as part of its mission to further consolidate and harmonize key application areas that are helping customers streamline their research and development processes.
Instem views the acquisition of NOTOCORD as another important and tangible step in its mission to help clients bring life enhancing products to market faster.
“The combined customers of NOTOCORD and Instem will be gaining a real advantage,” comments Philippe Zitoun, founder and Chief Executive Officer at NOTOCORD. “Our mission all along was to create technology that was easier and faster to use so our clients can do what they do best, every day. Since we were founded, we have relied on innovative and creative thinking to understand tomorrow’s needs in the marketplace. Becoming part of Instem will allow us to deliver more value, more quickly to more users everywhere. The entire team here at NOTOCORD is excited to be supported by a full complement of resources across Instem’s international offices. Instem shares in our commitment to excellence and is also well known for highly satisfied clients throughout all of the segments that they serve.”
One of the key strategic benefits of this next acquisition for Instem is its ability to more easily enhance its submit™ solution that is supporting FDA’s SEND mandate (Standard for the Exchange of Nonclinical Data) by integrating another key data collection source. The next version of the SEND standard (3.1) has recently been published, which now includes the initial requirements for Safety Pharmacology studies; this is in addition to the requirement for ECG data associated with toxicity studies supported by the current SEND 3.0 standard.
Instem also sees this as an opportunity to integrate data from NOTOCORD systems into its market-leading Provantis® software suite to provide a more seamless approach within preclinical study management, which will help its clients evaluate data and findings more efficiently.
“Notocord has a stellar reputation and a high quality team,” comments Phil Reason, Instem’s Chief Executive Officer. “Having known Philippe and their solutions for many years, we are confident that we will be successful together and that our clients will be very encouraged. As experts in safety pharmacology, the NOTOCORD team joins us just as this becomes a significant and additional focus area for SEND, one of our largest growth opportunities over the next several years. There are also some disruptive innovations in the safety pharmacology marketplace at the moment, so the timing was just right to bring them into the Instem group. We are in a strong position to increase their global reach and penetration with their existing products, while helping them fully launch new and exciting solutions.”
The NOTOCORD team and its applications will be aligned with Instem’s Preclinical Study Management Solutions group, which provides focused software solutions that empower organizations of all sizes to more efficiently collect, review, analyze and manage preclinical safety evaluation study data.
NOTOCORD will quickly be capitalizing on Instem’s global marketing, sales and support capabilities, while ensuring that its track record for delivering high-quality and highly reliable products continues to meet all of its clients’ requirements.